Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drug-induced cholestasis

S Erlinger1

  • 1Service d'Hépatologie, Hôpital Beaujon, Clichy, France. erlinger@bichat.inserm.fr

Journal of Hepatology
|January 1, 1997
PubMed
Summary
This summary is machine-generated.

Drug-induced cholestasis involves impaired bile secretion or bile duct obstruction. Various mechanisms, including transport system inhibition and cytoskeleton damage, contribute to this liver condition.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tuberculosis patients with higher levels of poverty face equal or greater costs of illness.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2019
Same author

Molecular repair of a defective CFTR protein in cystic fibrosis.

Clinics and research in hepatology and gastroenterology·2011
Same author

Sir James Black (1924-2010), β-blockers and liver disease.

Gastroenterologie clinique et biologique·2010
Same author

From MDR3 to LPAC: cross talk between molecular biology and clinical medicine.

Gastroenterologie clinique et biologique·2010
Same author

The Thalidomide renaissance.

Gastroenterologie clinique et biologique·2010
Same author

Hereditary haemorrhagic telangiectasia.

Gastroenterologie clinique et biologique·2010
Same journal

Anserine restores antibacterial immunity in cirrhosis via a protective CCL5-mediated hepatocyte-CD44<sup>+</sup>pDC crosstalk.

Journal of hepatology·2026
Same journal

Anti-CCL2-conjugated platelets attenuate early allograft and ischemia-reperfusion injury by inhibiting monocyte infiltration.

Journal of hepatology·2026
Same journal

A precision randomized trial of hepatitis C treatment support among people who inject drugs in India: The STOP-C Trial.

Journal of hepatology·2026
Same journal

Response to "Single-nucleus and spatial transcriptomic analyses reveal intra-tissue heterogeneity of PNPLA3".

Journal of hepatology·2026
Same journal

One-stop liquid biopsy: Can a single blood sample reveal the full spectrum of liver disease?

Journal of hepatology·2026
Same journal

Nocturnal insulin resistance and reduced insulin availability in human MASLD.

Journal of hepatology·2026
See all related articles

Area of Science:

  • Hepatology
  • Toxicology
  • Gastroenterology

Background:

  • Drug-induced cholestasis is a liver injury characterized by impaired bile flow.
  • It can manifest as hepatocellular dysfunction or bile duct obstruction.

Purpose of the Study:

  • To review the mechanisms and clinical presentations of drug-induced cholestasis.
  • To categorize different forms of drug-induced biliary pathology.

Main Methods:

  • Literature review of drug-induced cholestasis.
  • Analysis of mechanisms including transport inhibition, cytoskeleton damage, and immune responses.
  • Classification of cholestatic syndromes based on affected biliary structures.

Main Results:

  • Hepatocellular cholestasis involves impaired bile secretion, often linked to sex steroids.

Related Experiment Videos

  • Ductular/ductal cholestasis (cholangiopathy) can lead to ductopenia and cirrhosis.
  • Sclerosing cholangitis and gallstone formation are other potential drug-induced biliary effects.

    • Conclusions:

    • Drug-induced cholestasis presents diverse mechanisms and pathologies affecting bile secretion and ductal integrity.
    • Understanding these mechanisms is crucial for diagnosis and management of drug-induced liver injury.